Immunotherapy in Epidermal Growth Factor Receptor-mutant
Non-small Cell Lung Cancer / 中国肺癌杂志
Chinese Journal of Lung Cancer
; (12): 541-545, 2019.
Article
in Zh
| WPRIM
| ID: wpr-775593
Responsible library:
WPRO
ABSTRACT
Targeted therapy and immunotherapy are important treatments for non-small cell lung cancer (NSCLC). At present, the clinical and basic research of epidermal growth factor receptor (EGFR) mutation NSCLC is still in the exploratory stage, needing to optimize the efficacy, combination, sequence and dosage of immunotherapy and other treatments, to clarify the relationship between EGFR mutation, immune microenvironment and the efficacy of immunotherapy. In this review, we summarized the newly updated data about immunotherapy in EGFR mutant NSCLC in term of pre-clinical study, programmed cell death protein ligand 1 (PD-L1) expression, tumor mutation burden and treatment.
.
Full text:
1
Index:
WPRIM
Language:
Zh
Journal:
Chinese Journal of Lung Cancer
Year:
2019
Type:
Article